JGC
PCVX icon

J. Goldman & Co’s Vaxcyte PCVX Stock Holding History

J. Goldman & Co’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,700
Closed -$204K – 578
2024
Q2 		$204K Buy
+2,700
New +$184K 0.01% 405
2024
Q1 		– Sell
-17,694
Closed -$1.11M – 493
2023
Q4 		$1.11M Buy
17,694
+9,010
+104% +$468K 0.05% 226
2023
Q3 		$443K Sell
8,684
-367
-4% -$18.1K 0.02% 286
2023
Q2 		$452K Buy
9,051
+230
+3% +$10.9K 0.02% 297
2023
Q1 		$331K Sell
8,821
-28,219
-76% -$1.2M 0.01% 292
2022
Q4 		$1.78M Buy
37,040
+15,872
+75% +$623K 0.09% 185
2022
Q3 		$508K Buy
+21,168
New +$537K 0.02% 294

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

J. Goldman & Co's PCVX Position: Q3 2024 in Review

J. Goldman & Co sold out of Vaxcyte (PCVX) in Q3 2024, closing a stake of 2,700 shares — an estimated $204K sold.

J. Goldman & Co first reported a position in PCVX in Q3 2022 and held it in 7 quarters. The position peaked at $1.78M in Q4 2022. 328 funds tracked by Wall St. Rank hold PCVX as of Q3 2024.

  • J. Goldman & Co reported no remaining Vaxcyte position as of Q3 2024 after selling out during the quarter.
  • J. Goldman & Co sold 2,700 Vaxcyte shares in Q3 2024, an estimated $204K.
  • J. Goldman & Co first reported a position in Vaxcyte in Q3 2022 and held it in 7 quarters.
  • J. Goldman & Co's Vaxcyte position peaked at $1.78M in Q4 2022.
  • 328 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2024.

Based on J. Goldman & Co's 13F filing for Q3 2024, filed 14 Nov 2024.